Fengjuan Shi

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

Jingxin Li, Shipo Wu, Xiling Guo et al. · The Lancet Respiratory Medicine · 2022 · 164 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +8

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

Jingxin Li, Lihua Hou, Xiling Guo et al. · Nature Medicine · 2022 · 158 citations · Full text

Association of viral load with serum biomakers among COVID-19 cases

Fengjuan Shi, Tao Wu, Xiaojuan Zhu et al. · Virology · 2020 · 93 citations · Full text

Diagnostic Virology, Viral Load, Viral Persistence +7

Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial

Rong Tang, Hui Zheng, Busen Wang et al. · The Lancet Respiratory Medicine · 2023 · 48 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial

Pengfei Jin, Xiling Guo, Wei Chen et al. · PLoS Medicine · 2022 · 44 citations · Full text